Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Drug Recalls And Shortages - NAPLEX

  1. A 54-year-old female (height 168 cm, weight 74 kg) with hypertension is controlled on lisinopril 10 mg by mouth once daily. Due to a shortage, the prescriber switches her to benazepril 10 mg by mouth once daily. Baseline labs today: serum creatinine 0.9 mg/dL (normal 0.6–1.2), potassium 4.7 mEq/L (normal 3.5–5.0). Which monitoring parameter should be reassessed due to the medication change?
    Answer: Serum potassium and serum creatinine within 1–2 weeks after the ACE inhibitor switch This question tests monitoring requirements when switching between ACE inhibitors. The key patient-specific factor is that both medications are ACE inhibitors with similar effects on potassium and renal function, though the patient is switching to a different agent. Option A is correct because ACE inhibitors can cause hyperkalemia and affect renal function, and these parameters should be rechecked 1-2 weeks after any ACE inhibitor initiation or change, even when switching within the class. Option B (TSH) is unrelated to ACE inhibitor therapy. Option C (neutrophil count) is not routinely monitored for ACE inhibitors. Option D (magnesium) is not specifically affected by ACE inhibitors. The clinical pearl is that even when switching between agents in the same class, key safety parameters (potassium and renal function for ACE inhibitors) should be monitored to ensure the new agent is tolerated similarly to the previous one.
  2. A 4-year-old male (16 kg, 102 cm) with seasonal allergic rhinitis takes cetirizine oral solution 1 mg/mL: 5 mL by mouth once daily. Due to a national shortage of cetirizine solution, only cetirizine 5 mg chewable tablets are available. Which therapeutic alternative is most appropriate for this patient during the drug shortage?
    Answer: Cetirizine 5 mg chewable tablet by mouth once daily This question tests therapeutic alternatives during a cetirizine solution shortage for pediatric allergic rhinitis, emphasizing age-appropriate dosing. The key patient-specific factors are the 4-year-old's 5 mg daily dose and availability of 5 mg chewables. Cetirizine 5 mg chewable once daily is the best choice as it matches the prescribed dose in a suitable form for the child's age. 10 mg cetirizine or loratadine exceeds pediatric dosing, diphenhydramine causes excessive sedation with scheduled use. A transferable clinical pearl is that antihistamine dosing in children should adhere to age and weight guidelines to avoid overdose. Pharmacists should apply a framework assessing dose equivalence, formulation acceptability, and safety for pediatric switches.
  3. A 62-year-old female (height 160 cm, weight 70 kg) with type 2 diabetes takes metformin immediate-release 1000 mg by mouth twice daily and sitagliptin 100 mg by mouth once daily. She reports the pharmacy has been unable to fill her metformin for 2 weeks due to a regional supply shortage; her last hemoglobin A1c was 7.9% (goal <7% for many patients) and estimated glomerular filtration rate is 68 mL/min/1.73 m2^2. Which patient safety measure should be prioritized in this scenario?
    Answer: Coordinate with the prescriber to implement a temporary diabetes plan (e.g., metformin extended-release if available or alternative agent) and increase home glucose monitoring during the transition This question tests patient safety management during a drug shortage of a first-line diabetes medication. The key patient-specific factor is that the patient has been without metformin for 2 weeks with suboptimal glycemic control (A1c 7.9%) and adequate renal function for metformin use. Option C is correct because it prioritizes coordinated care with the prescriber to implement a safe alternative plan (such as metformin extended-release if available or another appropriate agent) while increasing monitoring during the transition to prevent glycemic deterioration. Option A is dangerous because glyburide has high hypoglycemia risk and the dosing is excessive. Option B is inappropriate because patients should not self-adjust diabetes medications without medical supervision. Option D is incorrect because sitagliptin can still provide benefit even without metformin, and stopping all therapy would worsen glycemic control. The clinical pearl is that drug shortages affecting chronic disease management require proactive prescriber collaboration, therapeutic alternatives, and enhanced monitoring to maintain disease control and prevent complications.
  4. A 29-year-old female (height 165 cm, weight 60 kg) presents to urgent care with uncomplicated pyelonephritis and is prescribed ciprofloxacin 500 mg by mouth twice daily for 7 days. Before dispensing, the pharmacy receives a recall notice for ciprofloxacin 500 mg tablets from a specific manufacturer due to contamination risk, and the recalled product is the only ciprofloxacin strength currently in stock. The patient has no drug allergies, is not pregnant, and has normal renal function. Which therapeutic alternative is most appropriate for this patient during the drug recall?
    Answer: Contact the prescriber to change therapy to trimethoprim-sulfamethoxazole double strength (160/800 mg) by mouth twice daily for 14 days if local susceptibility supports use This question tests appropriate antibiotic substitution during a drug recall for pyelonephritis treatment. The key patient-specific factor is uncomplicated pyelonephritis requiring effective oral therapy, with the prescribed fluoroquinolone unavailable due to contamination risk. Option B is correct because trimethoprim-sulfamethoxazole is an appropriate alternative for pyelonephritis when local susceptibility supports its use, the duration (14 days) is appropriate for this indication, and it involves prescriber communication for the therapeutic change. Option A is dangerous because dispensing contaminated medication violates patient safety. Option C is incorrect because azithromycin is not recommended for pyelonephritis and the duration is too short. Option D is inappropriate because nitrofurantoin doesn't achieve adequate tissue levels for pyelonephritis treatment despite being effective for cystitis. The clinical pearl is that pyelonephritis requires antibiotics with good tissue penetration and appropriate duration; during shortages, alternatives must be selected based on local resistance patterns with prescriber involvement.
  5. A 30-year-old male (75 kg, 182 cm) with type 1 diabetes uses insulin glargine 22 units subcutaneously nightly. His insulin glargine product is recalled, and the pharmacy dispenses an insulin glargine biosimilar at the same units. Which monitoring parameter should be reassessed due to the medication change?
    Answer: Fasting and premeal capillary blood glucose more frequently for several days after the switch This question tests monitoring parameters for insulin biosimilar switches during recalls, focusing on glycemic control. The key patient-specific factor is the type 1 diabetes requiring stable basal insulin without potency differences. Frequent fasting and premeal blood glucose checks is the best choice to detect variations in biosimilar response. INR, digoxin, and peak flow are irrelevant to insulin therapy. A transferable clinical pearl is that insulin changes warrant intensified self-monitoring for at least several days to adjust doses safely. Pharmacists should use a framework assessing diabetes type, monitoring frequency, and signs of dysglycemia for counseling.
  6. A 29-year-old female (60 kg, 168 cm) with community-acquired pneumonia is prescribed azithromycin 500 mg by mouth on day 1, then 250 mg by mouth daily on days 2–5. The pharmacy receives a recall for azithromycin 250 mg tablets due to labeling errors, and no unaffected stock is available; 500 mg tablets are available. Which therapeutic alternative is most appropriate for this patient during the drug recall?
    Answer: Use azithromycin 500 mg tablets by dispensing 500 mg on day 1, then instruct the patient to split the 500 mg tablet in half for days 2–5 if appropriate and permitted by product, and notify the prescriber of the recall-driven change This question tests therapeutic alternatives during an azithromycin recall, focusing on dose adjustment with available strengths for pneumonia. The key patient-specific factor is the Z-pack regimen requiring 500 mg day 1 then 250 mg daily. Using 500 mg day 1 and splitting 500 mg for subsequent 250 mg doses, if permitted, with prescriber notification is the best choice for regimen continuity. Dispensing recalled product risks error, incorrect dosing like 500 mg daily or doxycycline short course is suboptimal. A transferable clinical pearl is that tablet splitting may be used for dose approximation if the product allows and prescriber approves. Pharmacists should apply a framework evaluating available strengths, splitting feasibility, and communication.
  7. A 52-year-old female (68 kg, 163 cm) with hypertension is controlled on lisinopril 10 mg by mouth once daily; she also takes hydrochlorothiazide 25 mg by mouth once daily. Due to a manufacturer backorder, lisinopril will be unavailable for at least 2 months; her serum creatinine is 0.7 mg/dL and potassium is 4.0 mEq/L. Which monitoring parameter should be reassessed due to the medication change if she is switched to an alternative ACE inhibitor?
    Answer: Serum potassium and serum creatinine within 1–2 weeks after the switch This question tests monitoring parameters during an ACE inhibitor switch due to shortage, emphasizing electrolyte and renal surveillance. The key patient-specific factors are the patient's hypertension controlled on lisinopril and normal baseline potassium and creatinine. Assessing serum potassium and creatinine within 1–2 weeks is the best choice as ACE inhibitors can cause hyperkalemia or renal impairment, especially with concurrent diuretics. INR is irrelevant without anticoagulation, TSH and CK are not affected by ACE inhibitors. A transferable clinical pearl is that ACE inhibitor initiations or switches warrant renal function and potassium monitoring within 1–2 weeks to detect adverse effects early. Pharmacists should apply a framework evaluating drug class risks, concomitant medications, and patient comorbidities for monitoring plans.
  8. A 63-year-old male (80 kg, 176 cm) with atrial fibrillation takes warfarin 2 mg by mouth once daily and recently started trimethoprim-sulfamethoxazole for a skin infection. A recall is issued for his warfarin lot due to possible superpotency, and he is due for an INR check tomorrow. Which patient safety measure should be prioritized in this scenario?
    Answer: Replace recalled warfarin with a nonrecalled lot and ensure prompt INR assessment with close follow-up due to additive bleeding risk This question tests patient safety measures during a warfarin recall with concurrent interacting medication, prioritizing monitoring. The key patient-specific factors include superpotency risk, trimethoprim-sulfamethoxazole potentiating warfarin, and upcoming INR check. Replacing with nonrecalled warfarin and ensuring prompt INR assessment is the best choice to manage additive bleeding risks. Delaying testing risks undetected supratherapeutic INR, switching to clopidogrel lacks indication equivalence, adding vitamin K is inappropriate prophylaxis. A transferable clinical pearl is that drug interactions with warfarin necessitate closer INR monitoring during potency-related recalls. Pharmacists should apply a framework identifying interactions, replacing product, and scheduling follow-up.
  9. A 71-year-old male (78 kg, 174 cm) on warfarin 4 mg by mouth once daily for atrial fibrillation comes to the pharmacy after receiving a recall letter for his warfarin lot due to potential subpotency. He asks whether he should take extra tablets until he gets a new bottle. What is the most important counseling point for this substituted medication situation?
    Answer: Do not change the dose on your own; stop using the recalled lot and use the replacement as directed, with prompt INR follow-up as arranged This question tests patient counseling during a warfarin recall for subpotency, emphasizing safe transition. The key patient-specific factor is the risk of subtherapeutic anticoagulation if doses are self-adjusted. Advising against dose changes, stopping recalled lot, using replacement, and following INR plan is the best choice to prevent thrombosis or bleeding. Taking extra doses risks overdose on new lot, skipping doses causes gaps, vitamin K linkage is incorrect. A transferable clinical pearl is that patients should never self-adjust warfarin due to its narrow therapeutic index. Pharmacists should use a counseling framework stressing adherence, monitoring, and prescriber contact.
  10. A 38-year-old male (height 182 cm, weight 90 kg) with type 1 diabetes is switched from a recalled insulin glargine pen (device defect causing variable dosing) to an alternative insulin glargine product at the same prescribed dose (28 units subcutaneously nightly). The pharmacist dispenses the replacement and provides counseling. What is the most important counseling point for the substituted medication?
    Answer: Monitor blood glucose more frequently during the first 1–2 weeks after the switch and report recurrent hypoglycemia or hyperglycemia promptly This question tests patient counseling priorities when switching insulin products due to a recall. The key patient-specific factor is switching from a pen with variable dosing (device defect) to a properly functioning pen, which may result in different glycemic effects even at the same prescribed dose. Option C is correct because increased blood glucose monitoring during the transition period is essential to detect whether the patient experiences different glycemic control with the properly functioning device compared to the defective one. Option A is incorrect - insulin glargine pens are typically used for 28 days after first use. Option B is wrong because insulin glargine is a clear solution that should never be shaken. Option D is incorrect because insulin glargine is long-acting basal insulin typically given at bedtime or consistently at the same time daily, not with meals. The clinical pearl is that device-related recalls may have caused patients to unknowingly adapt to incorrect dosing, making the transition to proper dosing require careful monitoring.
  11. A 62-year-old female (88 kg, 160 cm) with type 2 diabetes takes metformin immediate-release 1000 mg by mouth twice daily, empagliflozin 10 mg by mouth once daily, and lisinopril 10 mg by mouth once daily. The pharmacy cannot obtain metformin immediate-release due to a regional supply disruption; only metformin extended-release 500 mg tablets are available. Her last hemoglobin A1c is 7.4% (goal <7% individualized) and serum creatinine is 0.8 mg/dL (normal 0.6–1.1). Which therapeutic alternative is most appropriate for this patient during the drug shortage?
    Answer: Switch to metformin extended-release 2000 mg by mouth once daily with the evening meal This question tests therapeutic alternatives for metformin during a shortage, focusing on formulation switches and dose equivalence in type 2 diabetes management. The key patient-specific factors are the patient's current 1000 mg twice daily immediate-release dose, hemoglobin A1c of 7.4%, and normal renal function. Switching to metformin extended-release 2000 mg once daily with the evening meal is the best choice as it maintains total daily dose and glycemic control with a convenient once-daily regimen. Twice-daily extended-release lacks the evening dosing benefit for tolerability, increasing empagliflozin without prescriber input is inappropriate, and 500 mg once daily is subtherapeutic. A transferable clinical pearl is that metformin IR to ER conversions typically match total daily dose, with ER taken with meals to minimize GI effects. Pharmacists should apply a framework evaluating renal function, A1c control, and patient adherence when selecting alternatives.
  12. A 6-year-old male (height 115 cm, weight 20 kg) with acute otitis media is prescribed amoxicillin 400 mg/5 mL oral suspension: 11 mL by mouth twice daily for 10 days (high-dose regimen). The pharmacy reports a shortage of amoxicillin suspension, but amoxicillin chewable tablets are available. The child can reliably chew tablets. What is the pharmacist's best action in response to the drug shortage?
    Answer: Convert to amoxicillin chewable tablets 250 mg: 3.5 tablets by mouth twice daily for 10 days This question tests dosage form conversion calculations during a drug shortage. The patient needs amoxicillin 880 mg (11 mL × 80 mg/mL) twice daily, requiring conversion to chewable tablets. To achieve 880 mg per dose using 250 mg tablets: 880 mg ÷ 250 mg/tablet = 3.52 tablets, which rounds to 3.5 tablets. Option B is correct with 3.5 tablets of the 250 mg strength twice daily providing the closest dose to the prescribed 880 mg. Option A (875 mg tablets) would provide a similar total dose but doesn't match the calculation. Option C (1.75 tablets of 500 mg) would give 875 mg, which is acceptable but the question asks for 250 mg tablet conversion. Option D (4 tablets of 250 mg) would provide 1000 mg, representing a significant overdose. The clinical pearl is that when converting between dosage forms during shortages, maintain the prescribed dose as closely as possible using available strengths, and consider the practicality of tablet splitting for pediatric patients.
  13. A 59-year-old female (72 kg, 164 cm) with hypertension is stable on lisinopril 20 mg by mouth once daily. Due to a shortage, she is switched to enalapril. Which therapeutic alternative is most appropriate for this patient during the drug shortage?
    Answer: Enalapril 20 mg by mouth once daily This question tests therapeutic alternatives for lisinopril during shortage, focusing on equipotent ACE inhibitor conversion. The key patient-specific factor is the stable 20 mg lisinopril dose for hypertension. Enalapril 20 mg once daily is the best choice as it provides direct dose equivalence. 10 mg or 2.5 mg are subtherapeutic, 40 mg exceeds equivalence risking hypotension. A transferable clinical pearl is that lisinopril and enalapril share 1:1 dose conversion for most patients. Pharmacists should employ a framework using conversion charts and monitoring blood pressure post-switch.
  14. A 39-year-old male (70 kg, 175 cm) presents to urgent care with dysuria and fever; urine culture is pending, and he is prescribed ciprofloxacin 500 mg by mouth twice daily for presumed pyelonephritis. The pharmacy receives an FDA recall notice for the specific lot of ciprofloxacin 500 mg tablets stocked due to potential contamination, and no nonrecalled ciprofloxacin is available today. The patient has no drug allergies and normal renal function (serum creatinine 0.9 mg/dL). Which therapeutic alternative is most appropriate for this patient during the drug recall?
    Answer: Substitute levofloxacin 750 mg by mouth once daily and notify the prescriber of the recall-driven change This question tests therapeutic alternatives during a ciprofloxacin recall for presumed pyelonephritis, emphasizing appropriate antibiotic selection and spectrum. The key patient-specific factors include the urgent infection, normal renal function, and no allergies. Substituting levofloxacin 750 mg once daily is the best choice as it provides equivalent fluoroquinolone coverage for pyelonephritis with convenient dosing and notifies the prescriber. Dispensing recalled product risks contamination, amoxicillin lacks sufficient spectrum for pyelonephritis, nitrofurantoin is inappropriate for upper urinary tract infections. A transferable clinical pearl is that during antibiotic recalls, select alternatives with similar spectrum, dosing, and efficacy based on guidelines like IDSA. Pharmacists should use a decision framework incorporating infection site, culture data, and patient factors for safe substitutions.
  15. A 27-year-old female (62 kg, 170 cm) with uncomplicated cystitis is prescribed trimethoprim-sulfamethoxazole double strength (160 mg/800 mg) by mouth twice daily for 3 days. The pharmacy receives a recall notice for the stocked lot due to incorrect tablet strength, and no unaffected lot is available today; she has no sulfonamide allergy, is not pregnant, and has normal renal function. Which therapeutic alternative is most appropriate for this patient during the drug recall?
    Answer: Nitrofurantoin monohydrate/macrocrystals 100 mg by mouth twice daily for 5 days This question tests therapeutic alternatives during a trimethoprim-sulfamethoxazole recall for uncomplicated cystitis, focusing on guideline-based options. The key patient-specific factors include the uncomplicated infection, normal renal function, and no allergies or pregnancy. Nitrofurantoin 100 mg twice daily for 5 days is the best choice as it is a first-line alternative with appropriate duration and spectrum for cystitis. Cephalexin dosing is incorrect (should be higher frequency), ciprofloxacin dosing is inadequate, dispensing recalled product risks error. A transferable clinical pearl is that UTI treatments should follow IDSA guidelines, prioritizing short courses for uncomplicated cases. Pharmacists should use a decision framework evaluating allergy, renal function, and local resistance for antibiotic substitutions.
  16. A 10-year-old male (32 kg, 140 cm) is prescribed oseltamivir oral suspension 6 mg/mL: take 10 mL by mouth twice daily for 5 days for influenza. Due to a shortage of oseltamivir suspension, only 30 mg capsules are available; the child can swallow capsules. Which therapeutic alternative is most appropriate for this patient during the drug shortage?
    Answer: Oseltamivir 60 mg by mouth twice daily for 5 days (two 30 mg capsules per dose) This question tests therapeutic alternatives during oseltamivir suspension shortage for pediatric influenza, focusing on weight-based dosing. The key patient-specific factors are the 32 kg weight requiring 60 mg twice daily and ability to swallow capsules. Oseltamivir 60 mg twice daily using two 30 mg capsules is the best choice as it matches the prescribed dose. 30 mg is subtherapeutic, 90 mg once daily alters regimen, zanamivir requires inhalation. A transferable clinical pearl is that antiviral dosing in children uses weight bands for equivalence during formulation shortages. Pharmacists should use a framework calculating dose from available strengths and assessing administration feasibility.
  17. A 69-year-old female (64 kg, 158 cm) on warfarin 3 mg by mouth once daily for prior deep vein thrombosis receives a pharmacy call that her specific lot is recalled due to potential glass particulate contamination. She reports no bleeding and her last INR 1 week ago was 2.3 (goal 2–3). How should the pharmacist document the recall intervention?
    Answer: Document recall lot number, patient notification, product disposition (quarantined/returned), prescriber communication, and plan for replacement and INR follow-up This question tests documentation requirements for drug recall interventions, emphasizing comprehensive records for patient safety and compliance. The key patient-specific factors include the warfarin recall for contamination, stable INR, and no symptoms. Documenting lot number, notification, disposition, prescriber communication, and follow-up plan is the best choice to ensure traceability and continuity of care. Minimal documentation risks oversight, instructing permanent discontinuation is inappropriate, avoiding patient profile entry limits accessibility. A transferable clinical pearl is that thorough recall documentation supports quality assurance and legal protection. Pharmacists should use a framework including all intervention details, communications, and resolutions for recalls.
  18. A 6-year-old female (20 kg, 112 cm) with acute otitis media is prescribed amoxicillin oral suspension 400 mg/5 mL: take 10 mL by mouth twice daily for 10 days. The pharmacy is experiencing a shortage of amoxicillin suspension but has amoxicillin 500 mg capsules available; the child can swallow small capsules with coaching. Which therapeutic alternative is most appropriate for this patient during the drug shortage?
    Answer: Amoxicillin 500 mg capsule by mouth three times daily for 10 days This question tests therapeutic alternatives during an amoxicillin suspension shortage for pediatric otitis media, focusing on dose equivalence and administration feasibility. The key patient-specific factors are the child's 20 kg weight requiring approximately 80 mg/kg/day and ability to swallow capsules. Amoxicillin 500 mg three times daily is the best choice as it approximates the prescribed 1600 mg daily dose with a standard regimen. Twice-daily 500 mg provides insufficient total dose, 250 mg twice daily is subtherapeutic, azithromycin is not first-line for otitis media. A transferable clinical pearl is that pediatric antibiotic dosing should prioritize weight-based calculations and guideline-recommended regimens during shortages. Pharmacists should employ a framework assessing swallowability, dose approximation, and prescriber notification for alternatives.
  19. A 60-year-old female (90 kg, 168 cm) with type 2 diabetes takes metformin immediate-release 850 mg by mouth three times daily, sitagliptin 100 mg by mouth once daily, and rosuvastatin 10 mg by mouth at bedtime. Metformin immediate-release is on shortage; metformin extended-release 500 mg tablets are available. Which therapeutic alternative is most appropriate for this patient during the drug shortage?
    Answer: Metformin extended-release 2000 mg by mouth once daily with the evening meal This question tests therapeutic alternatives for metformin during a shortage, emphasizing dose equivalence between formulations in type 2 diabetes. The key patient-specific factors are the patient's 850 mg three times daily immediate-release regimen totaling 2550 mg and availability of extended-release 500 mg tablets. Switching to extended-release 2000 mg once daily with the evening meal is the best choice as it approximates the maximum recommended dose with once-daily convenience. Lower doses like 500 mg or 1000 mg are subtherapeutic, pioglitazone introduces different risks without metformin continuity. A transferable clinical pearl is that metformin ER max is 2000 mg daily, often used for GI tolerability during switches. Pharmacists should employ a framework calculating total daily dose and assessing tolerability for formulation changes.
  20. A 57-year-old female (height 163 cm, weight 92 kg) with hypertension and type 2 diabetes is stable on lisinopril 20 mg by mouth once daily and amlodipine 5 mg by mouth once daily; most recent blood pressure is 128/76 mmHg and serum potassium is 4.5 mEq/L (normal 3.5–5.0). The wholesaler reports a temporary shortage of lisinopril tablets for at least 6 weeks. Which therapeutic alternative is most appropriate for this patient during the drug shortage?
    Answer: Switch to enalapril 10 mg by mouth twice daily This question tests therapeutic interchange during a drug shortage for an ACE inhibitor in a patient with diabetes. The key patient-specific factor is that the patient has diabetes, making ACE inhibitors or ARBs preferred for renal protection, and she is currently well-controlled on combination therapy. Option A is correct because enalapril 10 mg twice daily provides an equivalent ACE inhibitor dose to lisinopril 20 mg daily, maintaining the same drug class benefits including renal protection in diabetes. Option B (losartan 25 mg) is suboptimal because it's a low starting dose of an ARB that may not maintain blood pressure control. Option C (captopril 12.5 mg once daily) is incorrect due to inadequate dosing - captopril requires multiple daily doses and this is below the typical starting dose. Option D is inappropriate because discontinuing antihypertensive therapy for 6 weeks could lead to uncontrolled hypertension and loss of renal protection. The clinical pearl is that during ACE inhibitor shortages, switching to another ACE inhibitor at equivalent doses maintains therapeutic benefits, while ARBs are reasonable alternatives if ACE inhibitors are unavailable.

Start this quiz